Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00674960
Other study ID # GAAD-FD-CTP1
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received May 6, 2008
Last updated August 14, 2009
Start date May 2008
Est. completion date October 2009

Study information

Verified date August 2009
Source GAAD Medical Research Institute Inc.
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Pick's disease, also known as Pick disease,or FTD is a rare fronto-temporal neurodegenerative disease. This study will investigate the use of far infrared radiation for the control, management and treatment of Pick's disease.


Description:

This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date October 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- People with Pick's Disease

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Radiation:
Radiation: Far Infrared Radiation (5µm to 20µm wavelength)
Far Infrared Radiation (5µm to 20µm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Locations

Country Name City State
Canada The Centre for Incurable Diseases Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Therapy for FTD patients 1 year No
Secondary Rehabilitation of FTD Patients 1 Year No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04937452 - Dopaminergic Therapy for Frontotemporal Dementia Patients Phase 2
Completed NCT00077896 - Direct Current Brain Polarization in Frontotemporal Dementia Phase 1